SynthesisBMC pediatrics2026

Safety and efficacy of omalizumab in children aged 6 to 11 years with asthma: a systematic review and meta-analysis of randomized controlled trials.

Yi Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.